In addition, a nomogram that combined the risk signature and clinicopathological factors (age, Karnofsky performance score, grade and IDH1 status) was established to predict 1-, 3- and 5-year survival rate of glioma patients. This evidence concerns the gene IDH1 and central nervous system cancer.